76 related articles for article (PubMed ID: 15170819)
1. Isoflurane induces dopamine transporter trafficking into the cell cytoplasm.
Byas-Smith MG; Li J; Szlam F; Eaton DC; Votaw JR; Denson DD
Synapse; 2004 Aug; 53(2):68-73. PubMed ID: 15170819
[TBL] [Abstract][Full Text] [Related]
2. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain.
Harada N; Ohba H; Fukumoto D; Kakiuchi T; Tsukada H
Synapse; 2004 Oct; 54(1):37-45. PubMed ID: 15300883
[TBL] [Abstract][Full Text] [Related]
3. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging.
Lindsey KP; Wilcox KM; Votaw JR; Goodman MM; Plisson C; Carroll FI; Rice KC; Howell LL
J Pharmacol Exp Ther; 2004 Jun; 309(3):959-69. PubMed ID: 14982963
[TBL] [Abstract][Full Text] [Related]
4. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism.
Sorkina T; Hoover BR; Zahniser NR; Sorkin A
Traffic; 2005 Feb; 6(2):157-70. PubMed ID: 15634215
[TBL] [Abstract][Full Text] [Related]
5. Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex.
Zhu J; Apparsundaram S; Bardo MT; Dwoskin LP
J Neurochem; 2005 Jun; 93(6):1434-43. PubMed ID: 15935059
[TBL] [Abstract][Full Text] [Related]
6. Interaction of isoflurane with the dopamine transporter.
Votaw J; Byas-Smith M; Hua J; Voll R; Martarello L; Levey AI; Bowman FD; Goodman M
Anesthesiology; 2003 Feb; 98(2):404-11. PubMed ID: 12552200
[TBL] [Abstract][Full Text] [Related]
7. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations.
Chi L; Reith ME
J Pharmacol Exp Ther; 2003 Nov; 307(2):729-36. PubMed ID: 12975490
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Storch A; Hwang YI; Gearhart DA; Beach JW; Neafsey EJ; Collins MA; Schwarz J
J Neurochem; 2004 May; 89(3):685-94. PubMed ID: 15086525
[TBL] [Abstract][Full Text] [Related]
9. Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies.
Voll RJ; McConathy J; Waldrep MS; Crowe RJ; Goodman MM
Appl Radiat Isot; 2005 Sep; 63(3):353-61. PubMed ID: 15985372
[TBL] [Abstract][Full Text] [Related]
10. Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution.
Garcia BG; Wei Y; Moron JA; Lin RZ; Javitch JA; Galli A
Mol Pharmacol; 2005 Jul; 68(1):102-9. PubMed ID: 15795321
[TBL] [Abstract][Full Text] [Related]
11. Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation.
Johnson LA; Furman CA; Zhang M; Guptaroy B; Gnegy ME
Neuropharmacology; 2005 Nov; 49(6):750-8. PubMed ID: 16212991
[TBL] [Abstract][Full Text] [Related]
12. Covalent and noncovalent chemical modifications of arginine residues decrease dopamine transporter activity.
Volz TJ; Kim M; Schenk JO
Synapse; 2004 Jun; 52(4):272-82. PubMed ID: 15103693
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of dopamine transporter by iron chelation in vitro is mediated by altered trafficking, not synthesis.
Wiesinger JA; Buwen JP; Cifelli CJ; Unger EL; Jones BC; Beard JL
J Neurochem; 2007 Jan; 100(1):167-79. PubMed ID: 17227437
[TBL] [Abstract][Full Text] [Related]
14. Interaction between dopamine and its transporter: role of intracellular sodium ions and membrane potential.
Chen N; Reith ME
J Neurochem; 2004 May; 89(3):750-65. PubMed ID: 15086531
[TBL] [Abstract][Full Text] [Related]
15. Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells.
Chen N; Reith ME
J Neurochem; 2007 Apr; 101(2):377-88. PubMed ID: 17250655
[TBL] [Abstract][Full Text] [Related]
16. Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine.
Hashimoto K; Tsukada H; Nishiyama S; Fukumoto D; Kakiuchi T; Shimizu E; Iyo M
Ann N Y Acad Sci; 2004 Oct; 1025():231-5. PubMed ID: 15542721
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation.
Gorentla BK; Vaughan RA
Neuropharmacology; 2005 Nov; 49(6):759-68. PubMed ID: 16181646
[TBL] [Abstract][Full Text] [Related]
18. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
[TBL] [Abstract][Full Text] [Related]
19. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
20. Sp1 and Sp3 activate transcription of the human dopamine transporter gene.
Wang J; Bannon MJ
J Neurochem; 2005 Apr; 93(2):474-82. PubMed ID: 15816870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
